This article discusses a UK-based startup called Deep Blue Biotech, which is working on using cyanobacteria to produce high-value molecules such as hyaluronic acid. The company’s approach involves using photobioreactors to cultivate the bacteria and extract the desired compounds. The CEO of the company, Natasha Lomas, was interviewed for the article.
Here are some key points from the article:
- Deep Blue Biotech is a UK-based startup that uses cyanobacteria to produce high-value molecules such as hyaluronic acid.
- The company’s approach involves using photobioreactors to cultivate the bacteria and extract the desired compounds.
- The CEO of the company, Natasha Lomas, mentioned that the company has already secured funding from investors and is scaling up its operations.
- Deep Blue Biotech is not alone in this field, as other companies such as Microphyt and Bondi Bio are also working with cyanobacteria to produce similar products.
- However, Lomas believes that her company’s approach is more efficient and cost-effective than its competitors.
Some potential applications of the technology discussed in this article include:
- Producing hyaluronic acid for use in skincare products
- Developing new treatments for medical conditions such as joint pain and inflammation
- Creating sustainable alternatives to traditional materials used in industries such as textiles and construction
Overall, the article suggests that Deep Blue Biotech is a promising startup with a innovative approach to producing high-value molecules using cyanobacteria.